Rare disease focus Raptor operates in the rare diseases space with programs for nephropathic cystinosis, Huntington’s disease, and mitochondrial disorders, suggesting opportunities to position specialized therapies and leverage orphan drug designations for market access and partnerships.

Orphan designation leverage Existing orphan drug designations in the U.S. and EU can facilitate faster regulatory paths and favorable pricing discussions; explore co-development, licensing, or regional partnerships to maximize exclusivity windows.

Acquisition heritage Past acquisition by Horizon Therapeutics indicates a potential interest in scalable deals, portfolio integrations, or transitional partnerships; target alignment with Horizon’s ecosystem or similar players seeking rare-disease add-ons.

Mid-market potential Current revenue range and funding levels place Raptor in the mid-market bracket suitable for strategic collaborations, licensing, or co-development with larger biopharma while offering accessible entry points for boutique or specialty CRO/CMO partners.

Global IP strength Intellectual property surrounding cysteamine use in HD and other neurodegenerative diseases provides a foundation for sublicensing, adjuvant indications, or investigator-initiated studies that can be monetized through partner-driven research programs.